Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone in COVID-19 ARDS
NCT04325061Phase 4Terminated
- Sponsor
- Dr. Negrín University Hospital
- Start
- Apr 2020
- Primary completion
- Jun 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dexamethasone in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Dr. Negrín University Hospital. Primary endpoint: 60-day mortality. Started Apr 2020; status: terminated.
02
Drugs
dexamethasone
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04325061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04325061.